Dr. Patricia L. Kropf on Decitabine and Arsenic Trioxide in AML and MDS
Patricia L. Kropf, MD, discusses a combination of decitabine and arsenic trioxide as a replacement for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who cannot withstand induction chemotherapy.
Patricia L. Kropf, MD, assistant professor, Division of Bone Marrow Transplants, Fox Chase Cancer Center, discusses a combination of decitabine and arsenic trioxide as a replacement for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who cannot withstand induction chemotherapy. Kropf said decitabine is currently the standard of care in AML and MDS.
Kropf said her study treated patients with decitabine as a single agent, decitabine with carboplatin and decitabine with arsenic. She said the arm of the study that treated patients with decitabine and arsenic produced significantly better response rates than the other two arms, especially in newly-diagnosed AML. She added that there was no difference in toxicity between the three arms.
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
